Cysteinyl-leukotrienes induce vascular endothelial growth factor production in human monocytes and bronchial smooth muscle cells

Clinical and Experimental Allergy

Volumn 41, Issue 2, 2011, Pages 204-217

  Poulin, S ^a   Thompson, C ^a   Thivierge, M ^a   Veronneau S ^a   McMahon, S ^a   Dubois, C M ^a   Stankova, J ^a   Rola Pleszczynski, M ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Airway remodelling; Angiogenesis; AP 1; Cysteinyl leukotriene; Sp1

Indexed keywords

LUCIFERASE; MESSENGER RNA; MITHRAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDOLEUKOTRIENE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN;

AIRWAY REMODELING; ANGIOGENESIS; ARTICLE; ASTHMA; BRONCHUS MUSCLE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; MONOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TRANSACTIVATION;

EID: 78651443369     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2010.03653.x     Document Type: Article

References (57)

1. Green SA, Malice MP, Tanaka W, Tozzi CA, Reiss TF Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation. Thorax 2004; 59:100-4.
2. Devillier P, Baccard N, Advenier C. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part II: clinical studies with leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma. Pharmacol Res 1999; 40:15-29.
3. Hui Y, Funk CD. Cysteinyl leukotriene receptors. Biochem Pharmacol 2002; 64:1549-57.
4. Ciana P, Fumagalli M, Trincavelli ML et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 2006; 25:4615-27.
5. Heise CE, O'Dowd BF, Figueroa DJ et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275:30531-6.
6. Bosse Y, Pare PD, Seow CY. Airway wall remodeling in asthma: from the epithelial layer to the adventitia. Curr Allergy Asthma Rep 2008; 8:357-66.
7. Warner SM, Knight DA. Airway modeling and remodeling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol 2008; 8:44-8.
8. Bosse Y, Thompson C, McMahon S, Dubois CM, Stankova J, Rola-Pleszczynski M. Leukotriene D4-induced, epithelial cell-derived transforming growth factor beta1 in human bronchial smooth muscle cell proliferation. Clin Exp Allergy 2008; 38:113-21.
9. Espinosa K, Bosse Y, Stankova J, Rola-Pleszczynski M. CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J Allergy Clin Immunol 2003; 111:1032-40.
10. Porreca E, Di Febbo C, Di Sciullo A et al. Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb Haemost 1996; 76:99-104.
11. Thompson C, McMahon S, Bosse Y, Dubois CM, Stankova J, Rola-Pleszczynski M. Leukotriene D4 up-regulates furin expression through CysLT1 receptor signaling. Am J Respir Cell Mol Biol 2008; 39:227-34.
12. Henderson WR Jr, Chiang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173:718-28.
13. Walters EH, Soltani A, Reid DW, Ward C. Vascular remodelling in asthma. Curr Opin Allergy Clin Immunol 2008; 8:39-43.
14. Abdel-Rahman AM, el-Sahrigy SA, Bakr SI. A comparative study of two angiogenic factors: vascular endothelial growth factor and angiogenin in induced sputum from asthmatic children in acute attack. Chest 2006; 129:266-71.
15. Asai K, Kanazawa H, Kamoi H, Shiraishi S, Hirata K, Yoshikawa J. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy 2003; 33:595-9.
16. Simcock DE, Kanabar V, Clarke GW et al. Induction of angiogenesis by airway smooth muscle from patients with asthma. Am J Respir Crit Care Med 2008; 178:460-8.
17. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol 2001; 107:1034-8.
18. Kamio K, Sato T, Liu X et al. Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture. Am J Physiol Lung Cell Mol Physiol 2008; 294:L1226-32.
19. Breen EC. VEGF in biological control. J Cell Biochem 2007; 102:1358-67.
20. Lee CG, Link H, Baluk P et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances Th2-mediated sensitization and inflammation in the lung. Nat Med 2004; 10:1095-103.
21. Xie K, Wei D, Shi Q, Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 2004; 15:297-324.
22. Josko J, Mazurek M. Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 2004; 10:RA89-98.
23. Pages G, Pouyssegur J. Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc Res 2005; 65:564-73.
24. Kanayasu T, Nakao-Hayashi J, Asuwa N et al. Leukotriene C4 stimulates angiogenesis in bovine carotid artery endothelial cells in vitro. Biochem Biophys Res Commun 1989; 159:572-8.
25. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Leukotrienes C4 and D4 promote angiogenesis via a receptor-mediated interaction. Eur J Pharmacol 1994; 258:151-4.
26. Lee KS, Kim SR, Park HS, Jin GY, Lee YC. Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression. J Allergy Clin Immunol 2004; 114:1093-9.
27. Kanazawa H, Yoshikawa T, Hirata K, Yoshikawa J. Effects of pranlukast administration on vascular endothelial growth factor levels in asthmatic patients. Chest 2004; 125:1700-5.
28. Atakan A, Arikan H, Macunluoglu B et al. Renal protective effects of leukotriene receptor blockers in an experimental model of cyclosporine nephrotoxicity. Transplant Proc 2008; 40:279-84.
29. Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, Chung DC. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 2004; 64:1765-72.
30. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12:5447-54.
31. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11:72-82.
32. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin Cancer Res 2009; 15:492-501.
33. Thivierge M, Stankova J, Rola-Pleszczynski M. Toll-like receptor agonists differentially regulate cysteinyl-leukotriene receptor 1 expression and function in human dendritic cells. J Allergy Clin Immunol 2006; 117:1155-62.
34. Thompson C, Cloutier A, Bosse Y et al. Signaling by the cysteinyl-leukotriene receptor 2. Involvement in chemokine gene transcription. J Biol Chem 2008; 283:1974-84.
35. Thompson C, Cloutier A, Bosse Y et al. CysLT1 receptor engagement induces activator protein-1- and NF-kappaB-dependent IL-8 expression. Am J Respir Cell Mol Biol 2006; 35:697-704.
36. Risse G, Jooss K, Neuberg M, Bruller HJ, Muller R. Asymmetrical recognition of the palindromic AP1 binding site (TRE) by Fos protein complexes. EMBO J 1989; 8:3825-32.
37. Holgate ST. The airway epithelium is central to the pathogenesis of asthma. Allergol Int 2008; 57:1-10.
38. Salnikow K, Donald SP, Bruick RK, Zhitkovich A, Phang JM, Kasprzak KS. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 2004; 279:40337-44.
39. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26:3100-12.
40. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 1991; 88:1613-21.
41. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003; 111:S18-34; discussion S34-16.
42. Bindslev N. A homotropic two-state model and auto-antagonism. BMC Pharmacol 2004; 4:11-32.
43. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ 2008; 15:621-627.
44. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21:3995-4004.
45. Sandau KB, Faus HG, Brune B. Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem Biophys Res Commun 2000; 278:263-7.
46. Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60:1541-5.
47. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117:5965-73.
48. Diaz BV, Lenoir MC, Ladoux A, Frelin C, Demarchez M, Michel S. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem 2000; 275:642-50.
49. Rovati GE, Capra V. Cysteinyl-leukotriene receptors and cellular signals. SciWorld J 2007; 7:1375-92.
50. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007; 26:3203-13.
51. Hashimoto K, Ichiyama T, Hasegawa M, Hasegawa S, Matsubara T, Furukawa S. Cysteinyl leukotrienes induce monocyte chemoattractant protein-1 in human monocyte/macrophages via mitogen-activated protein kinase and nuclear factor-Kappab pathways. Int Arch Allergy Immunol 2009; 149:275-82.
52. Wierstra I. Sp1: emerging roles-beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 2008; 372:1-13.
53. Milanini-Mongiat J, Pouyssegur J, Pages G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 2002; 277:20631-9.
54. Tanaka T, Kanai H, Sekiguchi K et al. Induction of VEGF gene transcription by IL-1 beta is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. J Mol Cell Cardiol 2000; 32:1955-67.
55. Pore N, Liu S, Shu HK et al. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 2004; 15:4841-53.
56. Bradbury D, Clarke D, Seedhouse C, Corbett L, Stocks J, Knox A. Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J Biol Chem 2005; 280:29993-30000.
57. Noti JD, Reinemann BC, Petrus MN. Sp1 binds two sites in the CD11c promoter in vivo specifically in myeloid cells and cooperates with AP1 to activate transcription. Mol Cell Biol 1996; 16:2940-50.